US FDA mulls regulatory framework for bringing proteomic IVDs to patients
This article was originally published in Clinica
Executive Summary
The US FDA is considering how to develop a regulatory framework for validating research-level proteomic assays into in vitro diagnostics that can be used with patients in clinical practice.